BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Theravance, Inc. (THRX), Merck & Co., Inc. (MRK) Ink $153 Million Cardiovascular Pact


10/16/2012 8:54:25 AM

Theravance Inc. (THRX) signed a collaboration agreement with Merck & Co. (MRK) to develop and commercialize the biopharmaceutical company's product candidates for hypertension and heart failure in a deal valued at up to $153 million. Merck would receive exclusive global license to Theravance's drug candidates. Theravance will receive $5 million upfront and up to $148 million in milestone payments, as well as royalties from any products that come out of the collaboration. Large pharmaceutical companies such as Merck have been forming collaborations with smaller drug developers to help fill their pipelines as the industry grapples with a patent cliff. Theravance's other strategic collaborations include one with GlaxoSmithKline PLC (GSK, GSK.LN).



 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->